All In Biotech

Drug Trial Radar · NCT07529782

Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Chinese Patients With Plasma Cell Disorders Including Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Mar 17, 2026

Primary completion

Jun 30, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
Collaborators
Heidelberg Pharma AG
First posted
Apr 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a 2-part study with a dose-escalation part and a dose-expansion part. The aim of the dose-escalation part is to determine the maximum tolerated dose (MTD) and/or establish the recommended Phase 2 dose (RP2D) in the Chinese population, in order to select the treatment dose for the dose-expansion part. The dose-escalation part will be followed by the dose-expansion part once the MTD(s) and/or RP2D of HDP-101 monotherapy in the Chinese population have been determined. The dose-expansion part of the study is intended to collect preliminary evidence of antitumor activity and to confirm the safety of the HDP-101 as monotherapy in Chinese patients with r/r MM.

Conditions

  • Multiple Myeloma and Other Plasma Cell Neoplasms

Interventions

  • HDP-101Drug

    HDP-101 is available as lyophilized white powder for preparation of infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients who experience a dose-limiting toxicity (DLT) during the first cycle of treatment.Time frame: Up to Day 21 (from first dose)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chao-Yang Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China · Recruiting

  • Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.